SPX3,744.52-38.76 -1.02%
DIA299.23-3.56 -1.18%
IXIC11,073.31-75.33 -0.68%

Evercore ISI Group Upgrades Akero Therapeutics to Outperform, Raises Price Target to $50

Evercore ISI Group analyst Liisa Bayko upgrades Akero Therapeutics (NASDAQ:AKRO) from In-Line to Outperform and raises the price target from $10 to $50.

Benzinga · 09/14/2022 04:55
Evercore ISI Group analyst Liisa Bayko upgrades Akero Therapeutics (NASDAQ:AKRO) from In-Line to Outperform and raises the price target from $10 to $50.